Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1999, p. 2307-2310, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Cefoperazone Prevents the Inactivation of
1-Antitrypsin by Activated Neutrophils
Franco
Dallegri,*
Patrizia
Dapino,
Nicoletta
Arduino,
Maria
Bertolotto, and
Luciano
Ottonello
Department of Internal Medicine, University
of Genoa Medical School, Genoa, Italy
Received 11 March 1999/Returned for modification 16 April
1999/Accepted 11 June 1999
 |
ABSTRACT |
At sites of neutrophilic inflammation, tissue injury by neutrophil
elastase is favored by phagocyte-induced hypochlorous acid-dependent inactivation of the natural elastase inhibitor
1-antitrypsin. In the present study, cefoperazone
prevented
1-antitrypsin inactivation by neutrophils and
reduced the recovery of hypochlorous acid from these cells. Moreover,
the antibiotic reduced the free elastase activity in a neutrophil
suspension supplemented with
1-antitrypsin without
affecting the cells' ability to release elastase. These data suggest
that the drug inactivates hypochlorous acid before its reaction with
1-antitrypsin, thereby permitting the
antiprotease-mediated blockade of released elastase. In conclusion,
cefoperazone appears to have the potential for limiting
elastase-antielastase imbalances, attenuating the related tissue injury
at sites of inflammation.
 |
TEXT |
Human neutrophils are crucial in
protecting the host against infections (10). Nevertheless,
they also contribute to the damage of infected tissue sites (18,
24, 32). In this context, much attention has recently been
focused on neutrophil-derived proteases, primarily elastase (8,
12, 32), known to have broad proteolytic specificity and,
consequently, high potential to cause tissue destruction (8,
32). At sites of neutrophilic inflammation, including processes
elicited by microorganism invasion, the elastolytic activity is indeed
favored by the ability of phagocytes to inactivate natural
antiproteolytic systems, such as the elastase inhibitor
1-antitrypsin (
1-AT) (4, 5, 10, 19,
26). Taking into account this phenomenon, the idea of moderating
the protease-antiprotease imbalance at inflamed or infected tissue sites by protecting
1-AT from inactivation looks like an
attractive possibility to approach the treatment of tissue injury
pharmacologically. In the present study, we provide evidence for the
ability of a cephalosporin, cefoperazone, among other antibiotics, to
prevent
1-AT inactivation by neutrophils, reducing
elastase activity in the pericellular microenvironment.
Human neutrophils were isolated from heparinized venous blood by
dextran sedimentation and subsequent centrifugation on a Ficoll-Hypaque
density gradient as previously described (6). The
inactivation of
1-AT by neutrophils was accomplished by
incubating (30 min at 37°C) 2.5 × 106 neutrophils
with 125 µg of
1-AT (Calbiochem, San Diego, Calif.) and 10 ng of phorbol myristate acetate (Sigma Chemical Co., St. Louis,
Mo.) per ml in a final volume of 0.25 ml (22). At the end of
the incubation period, methionine (500 nmol) was added to quench
residual oxidants, and then the elastase inhibitory capacity of
1-AT in the supernatant was determined
spectrophotometrically (22) by testing its capacity to
inhibit porcine pancreatic elastase (PPE). Moreover, hypochlorous acid
(HOCl) generated by neutrophils was measured by the taurine-trapping
technique (33) as previously described (6),
whereas the ability of neutrophils to release elastase was studied by
measuring the capacity of cell-free supernatants to cleave the elastase
substrate methoxy-Ala-Ala-Pro-Val-p-nitroamilide (19). The capacity of
1-AT to complex with
PPE, after being incubated with HOCl (80 µM) in the presence of 100 µg of cefoperazone or cefotaxime per ml, was analyzed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as
previously described (7). Briefly, 4 µg of
1-AT was incubated with 1.6 µg of PPE for 30 min. The
samples were then heated at 100°C for 1.5 min in a solution containing 2% SDS (Bethesda Research Laboratories, Inc., Gaithersburg, Md.), 5%
-mercaptoethanol (Sigma), 0.001% bromophenol blue
(Sigma), and 65 mM Tris-HCl (pH 8.8). The samples were then analyzed by slab gel electrophoresis according to the method of Laemmli
(16) with a 3% polyacrylamide stacking gel (pH 6.8) and a
7.5% polyacrylamide resolving gel (pH 8.8). After electrophoresis,
protein bands were visualized with a silver stain (Bio-Rad, Richmond,
Calif.).
When exposed to 2.5 × 106 stimulated human
neutrophils for 30 min,
1-AT (125 µg) was completely
inactivated, as determined by its ability to inhibit PPE. As summarized
in Fig. 1, of the various antibiotics
tested, only cefoperazone prevented
1-AT inactivation
efficiently. Taking into account that neutrophils inactivate
1-AT with HOCl or another compound with similar
characteristics (22), the effects of antibiotics on the
recovery of HOCl from activated neutrophils were tested. At the
concentrations used herein, cefoperazone had inhibitory activity,
whereas other antibiotics were substantially inactive (Fig. 1).
Cefoperazone did not affect neutrophil O2
production and degranulation (data not shown), so interference with
cell activation is unlikely. On the contrary, it seems that the drug is
able to trap HOCl that is generated by neutrophils. Consistent with
this possibility, cefoperazone was capable of competing with taurine
for HOCl, thereby preventing the formation of taurine monochloramine
(Fig. 2). Moreover, the absorbance
spectrum of HOCl was changed by cefoperazone, consistent with the
reaction of the antibiotic with the oxidant. One possible explanation
of the present results is that HOCl or other neutrophil-derived
oxidants directly inactivate neutrophil elastase by a
cefoperazone-inhibitable process. In order to test this possibility,
the release of elastase from neutrophils was tested in the absence and
presence of cefoperazone. As shown in Fig.
3, activated neutrophils were capable of
releasing detectable levels of free elastase activity. The levels of
detectable enzymatic activity in the cell-free supernatants were
unaffected by the presence of cefoperazone, even at a concentration of
400 µg/ml. Thus, the effects of cefoperazone cannot be attributed to
a drug's ability to interfere directly with elastase activity. Moreover, the levels of elastase activity were unaffected by
1-AT (Fig. 3), suggesting that neutrophils inactivate
the antiprotease before it can react with released elastase. Finally,
cefoperazone caused a dose-dependent reduction of the elastase activity
released by neutrophils in the presence of
1-AT (Fig.
3). This means that the antibiotic prevented
1-AT
inactivation, thereby allowing an
1-AT-mediated blockade
of released elastase.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of various antibiotics on inactivation of
1-AT by neutrophils and on HOCl recovery from activated
cells. Each antibiotic was tested at 100 µg/ml, i.e., at micromolar
concentrations of 155 (cefoperazone), 219 (cefotaxime), 183 (ceftazidime), 277 (ofloxacin), 122 (rifampin), and 214 (tobramycin).
(A) Inactivation of 1-AT in the presence of various
antibiotics. Results are expressed as means ± 1 standard error of
the mean of four or five determinations, depending on the antibiotic.
Nil (no antibiotic) versus cefoperazone, P < 0.01; Nil
versus other compounds, P > 0.05 (Kruskal-Wallis
nonparametric analysis-of-variance test followed by Dunn's multiple
comparisons). EIC, elastase inhibitory capacity. (B) Effects of various
antibiotics on HOCl recovery from 106 neutrophils. Results
are expressed as means ± 1 standard error of the mean of three to
seven determinations, depending on the antibiotic. Nil versus
cefoperazone, P < 0.05; Nil versus other antibiotics,
P > 0.05 (Kruskal-Wallis nonparametric
analysis-of-variance test followed by Dunn's multiple comparisons).
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Cell-free interactions between HOCl and cefoperazone.
(A) Effects of different doses of cefoperazone on the recovery of
taurine monochloramine (Tau-NHCl) from a mixture of HOCl and taurine.
The experiments were carried out by adding ~35 nmol of HOCl to
mixtures of taurine plus cefoperazone (final volume of 1 ml). The
taurine concentration was 100 µM (constant). (B) Absorbance spectrum
of HOCl alone ( ) and in presence of cefoperazone ( ). HOCl and
cefoperazone concentrations were 1 mM in phosphate-buffered saline, pH
7.4; final solution, pH 7.4.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of various doses of cefoperazone on elastase
activity detectable in supernatants of neutrophils incubated in the
presence ( ) or absence ( ) of 1-AT (3.5 µg) under
the following conditions: neutrophils, 2 × 105;
phorbol myristate acetate, 10 ng/ml; final volume, 175 µl; and
incubation time, 60 min. Results are expressed as nanomoles of
substrate cleaved per hour by supernatants of neutrophils (mean ± 1 standard error of the mean, n - 4).
|
|
These results raise several considerations. In fact, at sites of
neutrophil inflammation, the tissue-protective
1-AT
screen can be overcome by excessive waves of extravascular neutrophil recruitment and, more easily, by the capacity of neutrophils to inactivate
1-AT (19, 27, 32). Taking into
account this neutrophil ability, we can imagine that neutrophil
elastase can easily digest major connective components, such as basal
membrane proteins, fibronectin, elastin, collagens, and proteoglycans
(10, 32). Consistent with this view, inactivated
1-AT as well as free and active elastase has been found
in fluids from inflamed tissues (1, 29, 34). In this
context, some anti-inflammatory drugs, such as 5-aminosalicylic acid
and sulfanilamide derivatives (primarily nimesulide and dapsone), have
been shown to prevent the inactivation of
1-AT by
neutrophils (21, 22), raising the possibility that they
protect the antiprotease shield from inactivation. Here, we present
evidence that the antibiotic cefoperazone was capable of trapping HOCl
so efficiently that it protected
1-AT from
neutrophil-mediated oxidation. Moreover, and probably more
interestingly, this antibiotic was also able to down-regulate the
expression of free elastase activity in a neutrophil suspension supplemented with
1-AT, i.e., under conditions
simulating the microenvironment at sites of inflammation. Thus, it
appears that cefoperazone can actually inactivate HOCl before its
reaction with
1-AT, thereby allowing
1-AT
interaction with and formation of a blockade for released elastase.
Therefore, owing to its potential to control elastase activity by
rescuing
1-AT, this antibiotic may alter the
protease-antiprotease balance, facilitating protection of infected
tissue sites. This seems to be particularly interesting in that the
concentrations of cefoperazone found to be effective herein can be
achieved in serum and in lung tissue after in vivo administration
(13, 23, 30).
It is known that HOCl is a strong oxidant able to react rapidly with
various chemical groups, such as primary amines, thiols, and thioethers
(22, 28). All the cephalosporins have at least one thioether
group. Moreover, the cephalosporins tested here have one additional
thioether group outside the cephalosporin ring. Consistent with these
structural characteristics, cephalosporins, including those found to be
ineffective herein, have been reported to scavenge HOCl efficiently
(2, 11, 17, 20). Nevertheless, these studies regarding the
ability of cephalosporins to react with HOCl were carried out with
relatively high drug concentrations and/or by preincubating the drugs
with HOCl before the addition of the HOCl substrate (2, 17,
20). However, when the drugs were incubated with HOCl and the
substrate simultaneously, no scavenging activity was observed at the
concentrations used herein (17). In this regard, Wasil and
coworkers observed a similar phenomenon with nonsteroidal
anti-inflammatory agents (31). Finally, compared with
previous findings of some of the authors of this paper (20),
a 20-fold reduction in the concentration of taurine used to trap HOCl
appears to increase the sensitivity of the assay, thereby uncovering a
particular affinity of cefoperazone for HOCl. In order to further test
this particular behavior of cefoperazone, HOCl was added to a mixture
of cefoperazone and
1-AT, and then the ability of
1-AT to complex with elastase was tested by SDS-PAGE. In
a parallel experiment, cefoperazone was replaced with cefotaxime. As
shown in Fig. 4, cefoperazone displayed
more potent
1-AT-protecting activity than cefotaxime. This is in agreement with the results of testing the elastase inhibitory capacity, shown in Fig. 1. Although the different
efficiencies of the various cephalosporins tested herein remain to be
fully understood, the activity of cefoperazone might be related to its ability to react with HOCl faster than other drugs react. This seems to
be in agreement with the concepts initially proposed by Wasil et al.
(31).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the interaction of 1-AT
incubated with HOCl in the presence of cefoperazone or cefotaxime. The
experiments were carried out by adding HOCl (80 µM) to mixtures of
1-AT (50 µg/ml) plus cefoperazone or cefotaxime (100 µg/ml). After incubation (15 min), the preparations were treated with
methionine, and aliquots containing 4 µg of 1-AT were
incubated with 1.6 µg of PPE for 30 min and analyzed by SDS-PAGE.
Lane 1, 1-AT plus PPE; lane 2, HOCl plus
1-AT and PPE; lane 3, HOCl plus cefoperazone,
1-AT, and PPE; lane 4, HOCl plus cefotaxime,
1-AT, and PPE.
|
|
Finally, as far as cefoperazone is concerned, it is unlikely that its
antioxidant activity can exert negative effects on the microbicidal
function of neutrophils. In fact, cephalosporins are not
cell-penetrating agents (25); therefore, very low levels of
these drugs can be expected to reach phagolysosomes, where bacterial
killing takes place. In conclusion, numerous studies have dealt with
the interplay between neutrophils and antimicrobial agents in the
attempt to identify antibiotics able to act synergistically with the
bacterial killing systems of neutrophils (25). More recently, the possibility of modulating exaggerated inflammatory responses to microbial invasion in tissues has gained interest. In
particular, it has been suggested that certain antimicrobial agents
have antioxidant properties (11, 15, 17, 20), thereby limiting the ability of neutrophils to lyse surrounding target cells
(2, 3, 20), i.e., by inference, limiting the ability of
neutrophils recruited at sites of inflammation to damage local parenchymal cells. On the other hand, in the attempt to design strategies to control connective tissue damage at sites of neutrophilic inflammation, it has been found that certain modified cephalosporins act as potent inhibitors of neutrophil elastase activity (9, 14). Although the best therapeutic approach to tissue injury in
infectious neutrophilic inflammatory reactions must be etiology driven,
i.e., must use appropriate antimicrobial treatments, the present study
provides a rational basis for encouraging the development of
antibiotics also having antiprotease-related histoprotective potential.
 |
ACKNOWLEDGMENTS |
This work was supported by grants to F.D. from Italian MURST.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Semeiotica
Medica 2, Dipartimento di Medicina Interna, Viale Benedetto XV n.6,
I-16132 Genoa, Italy. Phone: 39 010 3538940. Fax: 39 010 3538638. E-mail: otto{at}csita.unige.it.
 |
REFERENCES |
| 1.
|
Abbink, J. J.,
A. M. Kamp,
J. H. Nuijens,
T. J. G. Swaak, and E. C. Hack.
1993.
Proteolytic inactivation of 1-antitrypsin and 1-antichymotrypsin by neutrophils in arthritic joints.
Arthritis Rheum.
36:168-180[Medline].
|
| 2.
|
Cantin, A., and D. E. Woods.
1993.
Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro.
J. Clin. Investig.
91:38-45.
|
| 3.
|
Carreer, R.,
G. Deby-Dupont,
C. Deby,
L. Jadoul, and M. Mathy.
1998.
Oxidant-scavenging activities of beta-lactam agents.
Eur. J. Clin. Microbiol. Infect. Dis.
17:43-46[Medline].
|
| 4.
|
Carrell, R. W.
1986.
Alpha-1-antitrypsin: molecular pathology, leukocytes and tissue damage.
J. Clin. Investig.
78:1427-1431.
|
| 5.
|
Clark, R. A.,
P. J. Stone,
A. E. Hag,
J. D. Calore, and C. Franzblau.
1981.
Myeloperoxidase-catalyzed inactivation of 1-protease inhibitor by human neutrophils.
J. Biol. Chem.
256:3348-3353[Abstract/Free Full Text].
|
| 6.
|
Dallegri, F.,
A. Ballestrero,
G. Frumento, and F. Patrone.
1987.
Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes.
Blood
70:1743-1749[Abstract/Free Full Text].
|
| 7.
|
Dallegri, F.,
L. Ottonello,
P. Dapino, and C. Sacchetti.
1992.
Effect of nonsteroidal antiinflammatory drugs on the neutrophil promoted inactivation of alpha-1-proteinase inhibitor.
J. Rheumatol.
19:419-423[Medline].
|
| 8.
|
Dallegri, F., and L. Ottonello.
1997.
Tissue injury in neutrophilic inflammation.
Inflamm. Res.
46:383-391.
|
| 9.
|
Doherty, J. B.,
B. M. Ashe,
L. W. Argenbright,
P. L. Barker,
R. J. Bonney,
G. O. Chandler,
M. E. Dalghren,
C. P. Dorn, Jr.,
P. E. Finke,
R. A. Firestone,
D. Fletcher,
W. K. Hagmann,
R. Munford,
L. O'Grady,
A. L. Maycock,
J. M. Pisano,
S. K. Shah,
K. R. Thompson, and M. Zimmerman.
1986.
Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase.
Nature
322:192-194[Medline].
|
| 10.
|
Gallin, J. I.,
I. M. Goldstein, and R. Snyderman.
1992.
Inflammation. Basic principles and clinical correlates, 2nd ed.
Raven Press, New York, N.Y.
|
| 11.
|
Gunther, M. R.,
J. Mao, and M. S. Cohen.
1993.
Oxidant-scavenging activities of ampicillin and sulbactam and their effects on neutrophil functions.
Antimicrob. Agents Chemother.
37:950-956[Abstract/Free Full Text].
|
| 12.
|
Henson, P. M., and R. B. Johnston, Jr.
1987.
Tissue injury in inflammation: oxidants, proteinases, and cationic proteins.
J. Clin. Investig.
79:669-674.
|
| 13.
|
Kemmerich, B.,
H. Lode,
G. Belmega,
T. Jendroschek,
K. Borner, and P. Koeppe.
1983.
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
Antimicrob. Agents Chemother.
23:429-434[Abstract/Free Full Text].
|
| 14.
|
Knight, W. B.,
A. L. Maycock,
B. G. Green,
B. M. Ashe,
P. Gale,
H. Weston,
P. E. Finke,
W. K. Hagmann,
S. K. Shah, and J. B. Doherty.
1992.
Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives.
Biochemistry
31:4980-4986[Medline].
|
| 15.
|
Labro, M. T.,
J. El Benna,
N. Charlier,
H. Abdelghaffar, and J. Hakin.
1994.
Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome.
J. Immunol.
152:2447-2455[Abstract].
|
| 16.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 17.
|
Lapenna, D.,
L. Cellini,
S. De Gioia,
A. Mezzetti,
G. Ciofani,
D. Festi, and F. Cuccurullo.
1995.
Cephalosporins are scavengers of hypochlorous acid.
Biochem. Pharmacol.
49:1249-1254[Medline].
|
| 18.
|
Malech, H. L., and J. I. Gallin.
1987.
Neutrophils in human diseases.
N. Engl. J. Med.
317:687-694[Medline].
|
| 19.
|
Ossanna, P. J.,
S. T. Test,
N. R. Matheson,
S. Regiani, and S. Weiss.
1986.
Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interaction.
J. Clin. Investig.
77:1939-1951.
|
| 20.
|
Ottonello, L.,
F. Dallegri,
P. Dapino,
G. Pastorino, and C. Sacchetti.
1991.
Cytoprotection against neutrophil-delivered oxidant attack by antibiotics.
Biochem. Pharmacol.
42:2317-2321[Medline].
|
| 21.
|
Ottonello, L.,
P. Dapino,
G. Pastorino,
E. Vitale, and F. Dallegri.
1992.
The drug 5-aminosalicylic acid rescues 1-proteinase inhibitor from the neutrophil oxidative inactivation.
Digestion
51:140-145[Medline].
|
| 22.
|
Ottonello, L.,
P. Dapino,
M. C. Scirocco,
A. Balbi,
M. Bevilacqua, and F. Dallegri.
1994.
Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation?
Clin. Sci.
88:331-336.
|
| 23.
|
Srinivasan, S.,
E. L. Francke, and H. C. Neu.
1981.
Comparative pharmacokinetics of cefoperazone and cefamandole.
Antimicrob. Agents Chemother.
19:298-301[Abstract/Free Full Text].
|
| 24.
|
Styrt, B.
1989.
The role of phagocytes in non-infectious diseases, p. 145-169.
In
M. S. Klempner, B. Styrt, and J. Ho (ed.), Phagocytes and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands.
|
| 25.
|
Styrt, B.,
J. Ho, and M. S. Klempner.
1989.
Interactions between antimicrobial agents and phagocytes, p. 119-144.
In
M. S. Klempner, B. Styrt, and J. Ho (ed.), Phagocytes and disease. Kluwer Academic Publishers, Dordrecht, The Netherlands.
|
| 26.
|
Swaim, M. W., and S. V. Pizzo.
1988.
Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors.
J. Leukoc. Biol.
43:365-379[Abstract].
|
| 27.
|
Test, S. T., and S. J. Weiss.
1986.
The generation and utilization of chlorinated oxidants by human neutrophils.
Adv. Free Radic. Biol. Med.
2:91-116.
|
| 28.
|
Thomas, E. L.,
M. M. Jefferson, and M. B. Grisham.
1982.
Myeloperoxidase-catalyzed incorporation of amines into proteins: role of hypochlorous acid and dichloramines.
Biochemistry
21:6299-6308[Medline].
|
| 29.
|
Wallaert, B.,
B. Gresseir,
C. H. Marquette,
P. Gosset,
M. Remy-Jardin,
J. Mizon, and A. B. Tonnel.
1993.
Inactivation of 1-proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema.
Am. Rev. Respir. Dis.
147:1537-1543[Medline].
|
| 30.
|
Wartenberg, K.,
J. Tonak, and W. Knapp.
1983.
Lung tissue concentrations of cefoperazone.
Infection
11:280-282[Medline].
|
| 31.
|
Wasil, M.,
B. Halliwell,
C. P. Moorhouse,
C. Duncan,
S. Huthinson, and H. Baum.
1987.
Biologically-significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by some anti-inflammatory drugs.
Biochem. Pharmacol.
36:3847-3850[Medline].
|
| 32.
|
Weiss, S. J.
1989.
Tissue destruction by neutrophils.
N. Engl. J. Med.
320:565-576[Abstract].
|
| 33.
|
Weiss, S. J.,
R. Klein,
A. Slivka, and M. Wei.
1982.
Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation.
J. Clin. Investig.
70:588-607.
|
| 34.
|
Wong, P. S., and J. Travis.
1980.
Isolation and properties of oxidized alpha-1-proteinase inhibitor from human rheumatoid synovial fluid.
Biochem. Biophys. Res. Commun.
96:1449-1454[Medline].
|
Antimicrobial Agents and Chemotherapy, September 1999, p. 2307-2310, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.